Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Madrigal Pharmaceuticals (NASDAQ: MDGL) will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Madrigal Pharmaceuticals (NASDAQ: MDGL) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 1:30 PM PST. The presentation will be broadcast live and accessible via the company's Investor Relations Events and Presentations page, with a replay available after the event.
Details
News Market Reaction – MDGL
On Dec 16, the first trading day after this news, MDGL closed 1.07% below the previous close.
Data tracked by StockTitan Argus for the Dec 16 session.
Key Figures
- Conference date/time
- Jan 12, 2026 at 1:30pm PST
- J.P. Morgan Healthcare Conference presentation schedule
- Share price
- $571.44
- Pre-news current price
- 52-week high
- $605
- 52-week trading range high
- 52-week low
- $265
- 52-week trading range low
- Market cap
- $12,975,715,589
- Equity market capitalization pre-news
- Today’s volume
- 175,406 shares
- Trading volume before conference news
- 20-day avg volume
- 317,766 shares
- Average daily volume over last 20 sessions
- 200-day MA
- $377.22
- Long-term moving average level
Historical Context
-
Equity inducement grants to new non-executive employees under 2025 plan.
-
RSU inducement awards to three new non-executive employees.
-
Planned participation in three late-2025 healthcare investor conferences.
-
Phase 3 data showing Rezdiffra improved imaging tests and biomarkers in MASH cirrhosis.
-
Inducement RSU grants to 18 new non-executive employees.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on Monday, January 12, 2026 at 1:30pm PST.
The presentation will be broadcast live and can be accessed here or by visiting Madrigal’s Investor Relations Events and Presentations page. A replay of the webcast will be available after the event.
About Madrigal
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.